FOLH1 and neoplasm: For all modified peptides, a distinctly lower tumor accumulation (0.10 to 1.20% ID/g) at 24 h p.i. in comparison to the original [177Lu]Lu-PSMA-10 compound (9.82 ± 0.30% ID/g) could be observed with unchanging salivary gland uptake.